

## **ISBRG Corp launches SpotLight-19© Clinical Trial**

### **New R&D Funding Assistance Announced**

Mississauga, Ontario – May 12, 2021 - ISBRG Corp ([www.isbrgcorp.com](http://www.isbrgcorp.com)), a privately held data analytics company based in Southern Ontario, announces progress related to the ongoing development of its COVID-19 diagnostic device - SpotLight-19©. In addition to ISBRG's receipt of a Health Canada Investigational Testing Authorization (ITA), and the start of the company's clinical trial, ISBRG is announcing the addition of two new Advisory Board members, as well as the receipt of advisory services and conditional research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

#### **About SpotLight-19©**

ISBRG's SpotLight-19© is designed to leverage advancements in optics, artificial intelligence, and medical know-how to detect the presence of infection caused by multiple variants of the COVID-19 virus. SpotLight-19© uses light to scan the fingertip. The speed (less than 20-seconds) and cost of the test (approximately one dollar), combined with the non-invasive nature of the test (no body fluid of any kind is required), has the potential to test large numbers of people without the inconvenient delays and environmental damage associated with current chemical reagent-based tests.

#### **Clinical trial**

With R&D funding support from NRC IRAP, ISBRG will begin an investigational clinical trial of its prototype SpotLight-19© diagnostic technology. This follows the company's recent receipt of Investigational Testing Authorization (ITA) from Health Canada.

#### **Advisory Board Members**

ISBRG is pleased to announce that Mr. Ned Imbrie and Mr. Stephen Longfield have agreed to join ISBRG's Advisory Board. Ned was VP of Global Strategy and Business Development of Siemens Healthineers' Point of Care business. Stephen is the former VP Global Procurement of PepsiCo and is currently President of Tigerhawk Professional Services.

#### **About ISBRG**

The ISBRG artificial intelligence and optics-based technology platform is being developed by a team of physicians, AI specialists, product designers, communication specialists, an experienced and talented Advisory Board, and an alliance with one of North America's leading optical centres of excellence. ISBRG's technology platform has numerous applications in various stages of development, including but not limited to: SpotLight-19©, SpotLight-THC©, and SpotLight-HealthCheck©.

ISBRG's current Board of Advisors includes: Commander Chris Hadfield, internationally known author and astronaut; Michael Kelly, former Executive VP of Thousand Oaks based Amgen; Peter Bowler, the former President and CEO of Dallas based American Eagle Airlines; Irene d'Entremont, Order of Canada recipient and former Emera Board Member; Sylvia Augaitis, Executive Director – Wine Marketing Association of Ontario (VQA); Allan MacDougall, former CSIS Director General, Global Operations; and Will Sutherland, VP Business Development – The Kilmer Group.

For additional information please contact:

Austin MacIntyre  
VP Operations and Communications  
ISBRG Corp  
[amacintyre@isbrgcorp.com](mailto:amacintyre@isbrgcorp.com)

Or

Andrew Balfour  
Managing Partner  
Rubicon Strategy Inc.  
[Andrew@rubiconstrategy.com](mailto:Andrew@rubiconstrategy.com)